• Home
Search

Results for {phrase} ({results_count} of {results_count_total})

Displaying {results_count} results of {results_count_total}

More results...

Generic filters
Filter by Product categories
Bioactive Molecules
Amino Acids, Peptides, Proteins
Carbohydrates
Lipids, Fatty Acids
Metabolites
Phytochemicals
Vitamins
Bioactive Small Molecules
Biopolymers
Detection in Bioanalysis
Fluorescent Detection
Organic Pollutants & Pesticides
Fungicides
Herbicides
Insecticides
Other Pollutants
Pharmaceutically Actives
Antibiotics
API's & Intermediates
Steroids
Reagents and Building Blocks
Reagents for Life Sciences
Buffers
Building Blocks, Intermediates, Reagents
Fluorescent Detection
Linker
Non Fluorescent Detection & Chromogene Detection
Quorum Sensing
Uncategorized
    Lindenstrasse 77, CH-9000 St. Gallen, Tel: +41 71 244 48 25
    • 0Shopping Cart
    Chemodex
    • Home
    • Products
    • Catalogs
    • About Chemodex
    • Contact & Distributors
    • Menu Menu
    Everolimus

    Available from stock

      Inquiry

      Please fill out the form for your inquiry:



      * required field

      Everolimus

      SKU
      E0074

      Category: API's & Intermediates

      Synonyms
      42-O-(2-Hydroxyethyl)rapamycin , CERTICAN® , Afinitor®
      159351-69-6
      CAS-Number
      C53H83NO14
      Molecular Formula
      958.22
      Molecular Weight

      • Product Data
      • Handling
      • Safety Information
      • Details

      Specifications

      Purity
      ≥99% (HPLC)
      Identity
      IR
      Appearance
      White to off-white powder

      Properties

      Melting Point
      107-113 °C
      Solvents
      ethanol, methanol, DMF, DMSO
      Handling Advice
      Protect from light and moisture.
      Use / Stability
      Stable for at least 2 years after receipt when stored at -20°C.
      Long Term Storage
      -20°C
      Short Term Storage
      +4°C
      Shipping
      AMBIENT
      Transportation
      Not dangerous goods
      Signal word
      Danger
      GHS Symbol
      GHS08
      Precautionary statements
      P273-P314
      Hazard statements
      H372-H412
      Description
      Everolimus is a macrolide derived from rapamycin (sc-3504) with immunosuppressant properties shown to inhibit cell proliferation induced by growth factors. Macrolides belong to a group of antibiotics that bind to the 50S ribosomal subunit and inhibit protein synthesis. Studies indicate that everolimus is a mTOR (FRAP) inhibitor that displays high affinity toward the intracellular receptor FKBP12. Additionally, the Everolimus-FKBP12 complex decreases the activity of the S6K1 and 4EBP by binding to FRAP.
      InChi
      InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-
      References
      (1) H.J. Schuurman, et al., Transplantation 64, 32 (1997) , (2) W. Schuler, et al., Transplantation 64, 36 (1997) , (3) P. Neuhaus, et al., Liver Transpl. 7, 473 (2001) (Review) , (4) B. Nashan, Expert Opin. Investig. Drugs. 11, 1845 (2002) (Review) , (5) I. Beuvink, et al., Cell 120, 747 (2005) , (6) J.K. Patel & J.A. Kobashigawa, Expert Opin. Pharmacother. 7, 1347 (2006) (Review) , (7) P. Smolewski, Anticancer Drugs 17, 487 (2006) (Review) , (8) K. Zitzmann, et al., Neuroendocrinology 85, 54 (2007) , (9) Z. Zeng, et al., Blood 109, 3509 (2007) , (10) R. Bianco, et al., Br. J. Cancer 98, 923 (2008) , (11) A.I. Sanchez-Fructuoso, Expert Opin. Drug Metab. Toxicol. 4, 807 (2008) (Review) , (12) H.A. Lane, et al., Clin. Cancer Res. 15, 1612 (2009) , (13) D. Lebwohl, et al., Ann. N. Y. Acad. Sci. 1291, 14 (2013) (Review) , (14) U. Saran, et al., Clin. Sci. 129, 895 (2015) (Review) , (15) Morviducci, et al., Diabetes Res. Clin. Pract. (Epub ahead of print) (2018) (Review)
      InChi Key
      HKVAMNSJSFKALM-GKUWKFKPSA-N
      Smiles
      CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC

      Everolimus is a macrolide derived from rapamycin (sc-3504) with immunosuppressant properties shown to inhibit cell proliferation induced by growth factors. Macrolides belong to a group of antibiotics that bind to the 50S ribosomal subunit and inhibit protein synthesis. Studies indicate that everolimus is a mTOR (FRAP) inhibitor that displays high affinity toward the intracellular receptor FKBP12. Additionally, the Everolimus-FKBP12 complex decreases the activity of the S6K1 and 4EBP by binding to FRAP.

      SKU: E0074 Category: API's & Intermediates
      • Additional information

      Additional information

      Synonyms

      42-O-(2-Hydroxyethyl)rapamycin, CERTICAN®, Afinitor®

      Purity

      ≥99% (HPLC)

      Appearance

      White to off-white powder

      CAS-Number

      159351-69-6

      Molecular Formula

      C53H83NO14

      Molecular Weight

      958.22

      Identity

      IR

      Solvents

      ethanol, methanol, DMF, DMSO

      Melting Point

      107-113 °C

      Smiles

      CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC

      InChi Key

      HKVAMNSJSFKALM-GKUWKFKPSA-N

      Shipping

      AMBIENT

      Short Term Storage

      +4°C

      Long Term Storage

      -20°C

      Handling Advice

      Protect from light and moisture.

      Use / Stability

      Stable for at least 2 years after receipt when stored at -20°C.

      Hazard statements

      H372-H412

      Precautionary statements

      P273-P314

      GHS Symbol

      GHS08

      Signal word

      Danger

      Transportation

      Not dangerous goods

      References

      (1) H.J. Schuurman, et al., Transplantation 64, 32 (1997), (2) W. Schuler, et al., Transplantation 64, 36 (1997), (3) P. Neuhaus, et al., Liver Transpl. 7, 473 (2001) (Review), (4) B. Nashan, Expert Opin. Investig. Drugs. 11, 1845 (2002) (Review), (5) I. Beuvink, et al., Cell 120, 747 (2005), (6) J.K. Patel & J.A. Kobashigawa, Expert Opin. Pharmacother. 7, 1347 (2006) (Review), (7) P. Smolewski, Anticancer Drugs 17, 487 (2006) (Review), (8) K. Zitzmann, et al., Neuroendocrinology 85, 54 (2007), (9) Z. Zeng, et al., Blood 109, 3509 (2007), (10) R. Bianco, et al., Br. J. Cancer 98, 923 (2008), (11) A.I. Sanchez-Fructuoso, Expert Opin. Drug Metab. Toxicol. 4, 807 (2008) (Review), (12) H.A. Lane, et al., Clin. Cancer Res. 15, 1612 (2009), (13) D. Lebwohl, et al., Ann. N. Y. Acad. Sci. 1291, 14 (2013) (Review), (14) U. Saran, et al., Clin. Sci. 129, 895 (2015) (Review), (15) Morviducci, et al., Diabetes Res. Clin. Pract. (Epub ahead of print) (2018) (Review)

      InChi

      InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-

      Quantity

      100 mg, 250 mg, Bulk

      Related products

      • Flibanserin

        Flibanserin

        Purity: ≥98% (HPLC)CAS-Number: 167933-07-5SKU: F0337

        Read more Show Details
      • Articaine hydrochloride

        Articaine hydrochloride

        Purity: ≥98% (HPLC)CAS-Number: 23964-57-0SKU: A0564

        Read more Show Details
      • Brinzolamide

        Brinzolamide

        Purity: ≥98% (HPLC)CAS-Number: 138890-62-7SKU: B0424

        Read more Show Details
      • Diclofenac acid

        Diclofenac acid

        Purity: ≥98% (HPLC)CAS-Number: 15307-86-5SKU: D0147

        Read more Show Details
      © Copyright - Chemodex Ltd. - Customized Molecules developed in Switzerland
      • Home
      • All products
      • Order and delivery information
      • Disclaimer
      • Privacy policy
      • About this site
      Epoxidized soya bean oil Epoxidized soya bean oil Enalaprilat Enalaprilat Scroll to top